The Reston, Va., home builder recorded net income of $333.7 million, or $108.54 a share, for the second quarter, down from $400.9 million, or $120.69 a share, in the prior year period. Analysts polled ...

Solid Biosciences said federal regulators have granted its fast-track designation for the company's investigational gene therapy for the treatment of a heart rhythm condition.

Shares of Cambridge, Mass.-based Sarepta have fallen by more than 90% in the last year amid safety concerns about its Elevidys, a gene therapy that treats Duchenne muscular dystrophy, following ...

BNY, the world's largest custodian bank, will employ blockchain technology developed by investment bank Goldman Sachs to maintain a record of customers' ownership of select money market funds. The ...

The French-fry maker on Wednesday said its cost-savings program is expected to deliver at least $250 million of annualized run-rate savings by the end of fiscal 2028. The cost savings include a ...

Revolution Medicines was granted breakthrough therapy designation for elironrasib, a potential non-small cell lung cancer treatment.

My husband recently received a $50,000 inheritance. We have no idea what to do with it. We want to be wise, but everything is so confusing. I have early Alzheimer’s and have trouble organizing my ...

U.K. banks are set to start reporting results for the second quarter of 2025 this week. Here's what you need to know: LLOYDS BANKING GROUP: Lloyds reports on Thursday and the bank-provided consensus, ...

Apple on Wednesday unveiled AppleCare One, which provides customers with warranty coverage for multiple Apple devices under one plan. The new plan will cost $19.99 per month and allow customers to ...

Alphabet is due to post its second-quarter earnings after Wednesday's closing bell. Investors will be focused on the state of ...

Alphabet's stock has gotten into positive territory for the year, with its stock on a recent hot streak. Both the Class A and Class C shares rose for ten sessions in a row through Tuesday's close. Tha ...

American depositary receipts of French biotechnology firm Abivax rose more than sixfold premarket after a drug candidate for bowel condition ulcerative colitis showed promise in a late-stage clinical ...